Ascensia Diabetes Care launches CONTOURCOMFORT pen needles in Germany, Austria and Switzerland

  • Ascensia Diabetes Care, a PHC Holdings unit, launched CONTOUR COMFORT pen needles, expanding its CONTOUR diabetes-care portfolio.
  • Pharmacy rollout starts June 1, 2026 in Germany, Austria, Switzerland, with broader international expansion planned over two years.
  • Product targets improved injection stability and depth control via a hexagonal anti-tilt base, aiming to reduce intramuscular injection risk.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PHC Holdings Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202606010300BIZWIRE_USPR_____20260601_BW917225) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.